Tags

  • Sorting

  • Filters

Developing a method for nitrosamine analysis in pharmaceutical products

In our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly encountered nitrosamines in pharmaceuticals and ways to address specific challenges with their analysis.

Top 7 Echo® MS System customer questions—answered

You asked, we answered! The Echo® MS System launched earlier this year, and has created a buzz in the industry, with analysis speeds of up to 3 samples per second. This is up to 50x faster than the conventional LC-MS/MS.  This revolutionary tool for drug discovery and...

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.

Five Ways to Transform Your Therapeutic Quantification Studies with One Solution